Data from phase III trial of Sublocade in opioid use disorder published in Journal of Addiction Medicine
Indivior announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status and healthcare resource utilization) of Sublocade (buprenorphine extended-release) injection for subcutaneous use in opioid use disorder by the Journal of Addiction Medicine. These measures were collected during the 24-week, Phase III, randomized, placebo-controlled study assessing the drug's efficacy, safety and tolerability.
The results showed that participants receiving Sublocade versus placebo experienced significant changes from baseline on the EQ-5D-5L index (300/300mg: difference=0.0636) and visual analog scale (300/300mg: difference=5.9, 300/100mg: difference=7.7), and on the SF-36v2 physical component summary score (300/300mg: difference=3.8; 300/100mg: difference=3.2). Treatment satisfaction was significantly higher at the end of study for participants receiving Sublocade 300/300mg and 300/100mg than placebo. Employment increased by 10.8% with Sublocade 300/300mg and 10.0% with 300/100mg but decreased by 12.6% with placebo. Participants receiving Sublocade compared with placebo had significantly fewer hospital days per person-year observed.
See: "Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study." Ling W et al. J Addict Med. March 2019 DOI: http://dx.doi.org/10.1097/ADM.0000000000000517
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cevenfacta, intended for the treatment of bleeding episodes.
Calliditas Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) greater than 1.5 g/gram.